Vasoactive Intestinal Peptide (Vip) Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Vasoactive intestinal peptide (VIP) neurons are a major neuromodulatory class in cortical, hippocampal, and hypothalamic circuits, defined by VIP peptide production and signaling through VPAC1/VPAC2 receptors.[1][2] In the cortex, many VIP cells are disinhibitory interneurons that preferentially inhibit other inhibitory populations (especially somatostatin interneurons), thereby gating pyramidal-cell recruitment and state-dependent information flow.[3][4]
Because VIP systems regulate circadian synchronization, inflammatory tone, and synaptic gain, they sit at a convergence point between network instability and molecular stress responses relevant to Alzheimer's disease, Parkinson's disease, and other neurodegenerative syndromes.[2:1][5]
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0002269 | vasoactive intestinal peptide secreting cell | Medium |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0002269 | vasoactive intestinal peptide secreting cell |
VIP neurons are molecularly heterogeneous, including cortical bipolar/bitufted populations and suprachiasmatic nucleus VIP neurons that function as circadian coupling hubs.[6][7] VIP release elevates cAMP signaling in target neurons and glial cells, with downstream effects on excitability, oscillatory coherence, vascular tone, and cytokine programs.[1:1][2:2]
In sensory and association cortex, VIP-mediated disinhibition can transiently increase signal throughput during attention or arousal states. This mechanism is relevant to cognitive symptoms in neurodegeneration, where impaired inhibitory balance contributes to network hypersynchrony and reduced adaptive plasticity.[3:1][4:1]
Within the SCN, VIP is a core synchronizing signal that aligns single-cell oscillators into a coherent circadian network.[6:1][8] Disruption of VIP signaling degrades rhythm amplitude and phase coherence, which is mechanistically relevant to sleep-wake and autonomic disturbances frequently observed early in AD and PD.[5:1][9]
Beyond SCN circuits, VIP neurons interact with hypothalamic and brainstem centers controlling arousal and thermoregulation, linking peptide signaling to fatigue, sleep fragmentation, and day-night blood pressure abnormalities that track disease burden in synucleinopathies.[5:2][9:1]
VIPergic interneuron dysfunction has been associated with altered cortical inhibition and impaired circuit timing in AD-relevant networks.[10] VIP signaling also exhibits anti-inflammatory and trophic effects that may counter glial-mediated synaptic injury.[2:3][11]
In PD, degeneration of monoaminergic systems changes cortical and hypothalamic neuromodulatory context, potentially amplifying downstream consequences of VIP circuit dysregulation on sleep, autonomic function, and executive processing.[5:3][12]
Given that VIP neurons coordinate inhibition, vascular coupling, and immune signaling, they are plausible modifiers of vulnerability across tauopathies and synucleinopathies where circuit-level compensation delays overt clinical decline.[10:1][11:1]
VIP/VPAC pathways are being explored for neuroprotection and anti-inflammatory modulation, but translation requires receptor-selective targeting and careful management of peripheral effects (for example vasodilation or gastrointestinal responses).[1:2][11:2] A practical strategy is mechanism-guided stratification using combined circadian metrics, inflammatory biomarkers, and network-physiology readouts to identify patients with VIP-axis dysfunction.[8:1][12:1]
Potential intervention classes include peptide analogs, receptor-biased agonists, and circuit-level neuromodulation approaches that restore disinhibitory balance and circadian coherence rather than only suppressing symptoms.[6:2][8:2]
The study of Vasoactive Intestinal Peptide (Vip) Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Said SI, Dickman KG. Pathways of inflammation and cell death in the target organ: the role of VIP as anti-inflammatory and cytoprotective agent. Peptides. 2007. ↩︎ ↩︎ ↩︎
Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Trends Immunol. 2012. ↩︎ ↩︎ ↩︎ ↩︎
Pi HJ, Hangya B, Kvitsiani D, et al. Cortical interneurons that specialize in disinhibitory control. Nature. 2013. ↩︎ ↩︎
Pfeffer CK, Xue M, He M, et al. Inhibition of inhibition in visual cortex: the logic of connections between molecularly distinct interneurons. Nat Neurosci. 2013. ↩︎ ↩︎
Videnovic A, Golombek D. Circadian and sleep disorders in Parkinson's disease. Mov Disord. 2013. ↩︎ ↩︎ ↩︎ ↩︎
Aton SJ, Colwell CS, Harmar AJ, Waschek J, Herzog ED. Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat Neurosci. 2005. ↩︎ ↩︎ ↩︎
Abrahamson EE, Moore RY. Suprachiasmatic nucleus in the mouse: retinal innervation, intrinsic organization and efferent projections. Brain Res. 2001. ↩︎
Mazuski C, Abel JH, Chen SP, et al. Entrainment of circadian rhythms depends on firing rates and neuropeptide release of VIP SCN neurons. Neuron. 2018. ↩︎ ↩︎ ↩︎
Leng Y, Musiek ES, Hu K, et al. Association between circadian rhythms and neurodegenerative diseases. Nat Rev Neurol. 2019. ↩︎ ↩︎
Hijazi S, Heistek TS, Scheltens P, et al. Early restoration of parvalbumin interneuron activity prevents memory loss and network hyperexcitability in a mouse model of Alzheimer's disease. Neuron. 2019. ↩︎ ↩︎
Gozes I, Furman S, Ashur-Fabian O. VIP and related peptides in neuroprotection and neurodegenerative disease. Curr Pharm Des. 2009. ↩︎ ↩︎ ↩︎
Videnovic A, Lazar AS, Barker RA, Overeem S. ‘The clocks that time us’ - circadian rhythms in neurodegenerative disorders. Nat Rev Neurol. 2014. ↩︎ ↩︎